Precision Biotherapeutics

India's Genetic Mosaic Meets Precision Biotherapeutics

India accounts for 65% of deaths from non-communicable diseases globally, a harrowing statistic that cuts across urban and rural divides. The burgeoning demand for targeted medical interventions has paved the way for precision biotherapeutics. With India’s genetic diversity—spanning over 4,000 ethnic groups—the “one-size-fits-all” pharmaceutical approach can no longer persist. This is where precision biotherapeutics emerges as both a promise and a challenge. But how does this nascent field navigate the complexity of India’s health landscape?

Why India Can’t Rely on Conventional Therapies

Precision biotherapeutics, unlike traditional methods, tailors treatments to genetic, molecular, or cellular profiles. This specificity is especially critical in managing diseases like cancer or rare genetic disorders. Conventional chemotherapy for cancer, for instance, often harms healthy cells alongside malignant ones, leading to severe side effects and reduced efficacy. Biologics, CRISPR-based gene editing, and mRNA therapeutics promise precision, limiting collateral damage. Yet for India, systemic challenges remain—chiefly affordability and infrastructure.

The genetic diversity of India magnifies these stakes. Large-scale genomic studies, such as those led by the Institute of Genomics and Integrative Biology, have shown stark genetic variation across ethnic groups. The implication? A drug tested on populations in Europe may yield entirely different efficacy results within India. This calls for homegrown solutions—but are we equipped?

The Machinery Behind the Promise

Structurally, policy optimism is evident. Precision biotherapeutics has been named one of the six focus areas under India’s Biotechnology for Economy, Environment, and Employment Framework. Research institutions like the Translational Health Science and Technology Institute and the National Institute of Biomedical Genomics are mapping disease susceptibilities unique to Indian subpopulations. Meanwhile, private players like Biocon and Zydus Cadila are scaling investment into biologics and gene therapies.

But there’s a glaring absence of clear regulatory guidance. The Drugs and Cosmetics Act, 1940, which governs medical interventions, has not evolved to accommodate cutting-edge systems like CRISPR or AI-driven discovery. Currently, guidelines limit the therapeutic use of emerging technologies, but fail to define the scope of “therapy.” This regulatory void means uneven implementation, hindering investor confidence in the sector.

Moreover, unlike mature economies, India’s capacity to manufacture biologics remains limited—restricted to a few players with advanced labs and requisite expertise. The cost barrier compounds this: cell therapies and gene-editing systems can run into tens of lakhs per treatment cycle, pricing out lower- and middle-income segments.

What the Data Shows—And What It Obscures

The government is keen to pitch India as a cost-effective hub for precision therapies. With the global precision medicine market projected to exceed $22 billion by 2027, India’s affordable manufacturing capacities could provide a competitive edge. Yet affordability is not an across-the-board trait. Advanced therapies, particularly monoclonal antibodies, cost upwards of ₹8-12 lakh per patient annually—a price point that excludes 70% of households earning below ₹10,000 per month.

Infrastructure and expertise issues amplify these concerns. India only has an estimated 15-16 high-grade biologics labs capable of handling large-scale clinical trials—a vast shortfall compared to countries like South Korea, where investments in biotherapeutics tripled between 2018 and 2022. While the Department of Biotechnology projects funding allocations to surpass ₹15,000 crore for biotech research, much of this investment has been earmarked for genomics mapping rather than manufacturing capabilities. The imbalance is concerning.

The Uncomfortable Questions

The government envisions India as a hub for precision biotherapeutics, but recruitment for trials across diverse demographic groups remains weak. How can therapies tailored to genetic profiles be effective if clinical trials disproportionately enlist urban populations? India’s regulatory apparatus also lacks frameworks for data protection. Genomic data—a cornerstone for designing precision therapies—could be misused by private entities, leading to ethical breaches or discriminatory profiling.

Another structural flaw revolves around long-term scale. Precision therapies often rely on expensive imports for reagents, raising dependency concerns. The timeline for building robust local supply chains—particularly for nucleic acid-based systems—is unrealistic given existing gaps in technical capacity. Without systematic investment in education and skill development, any achievements in precision biotherapeutics might remain siloed within elite research institutes, failing to reach grassroots health networks.

Lessons from South Korea’s Rapid Biopharma Scaling

South Korea offers a sharply contrasting trajectory in precision biotherapeutics. Between 2018 and 2022, the government injected $3.5 billion directly into gene-editing research and established genomic sequencing centers, scaling domestic capacity to near self-reliance. Critically, a targeted policy expanded clinical trial access beyond major cities, integrating rural populations into genomic studies. India, by contrast, remains overly reliant on imported expertise and has yet to align genomic mapping efforts with trial participation frameworks.

South Korea also implemented stringent data privacy measures under its Personal Information Protection Act. This safeguarded citizen genomics data while ensuring private investment continued flowing steadily into bio-startups. India’s own lack of comprehensive data legislation—such as a genomic privacy policy or explicit clauses under the Digital Personal Data Protection Act—places its aspirations at risk.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions